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Abstract
Background: Recent advances in cancer therapeutics have resulted in significantly improved overall survival and
progression-free survival for patients. Targeted oral systemic anticancer therapies (SACT) offer a range of treatment
approaches that differ from traditional cytotoxic chemotherapy: non-cytotoxic oral SACT target malignant disease
continuously, have less broad and more favourable safety profiles, which can improve patients’ quality of life (QoL).
Toxicities associated with daily oral SACT administration can, however, result in non-adherence and a reduced QoL.
Non-conventional dosing of oral SACT, where unlicensed doses/schedules of drugs are prescribed, is one approach
increasingly adopted by clinicians to reduce toxicities and subsequent non-adherence and to improve QoL.
Guidance governing this practice is, however, limited. This systematic review aims to identify evidence about
prescribing practices of, and outcomes from, non-conventional dosing of oral SACT in oncology and malignant
haematology.
Methods: A search using the following electronic databases will be conducted: Ovid MEDLINE, Ovid EMBASE,
Cumulative Index to Nursing and Allied Health Literature (CINAHL) and Cochrane Registry of Controlled Trials. Studies will
be selected based on predefined inclusion/exclusion criteria. Critical appraisal will be conducted to identify potential
biases, strengths and limitations of included studies. Extracted data will be tabulated to sort and summarise key findings.
An initial literature search indicated that studies reporting non-standard dosing of oral SACT intervention studies are
diverse and heterogeneous in study design. Extracted data will, therefore, be tabulated, and together with a narrative
synthesis of integrated key findings, will be presented and discussed in reference to the strengths and weaknesses of the
evidence base. If sufficient stratified data is available (e.g. age group, tumour type, disease stage) or intervention (drug,
dosing schedule), sub-group analysis will be conducted to inform prescribing practice.
Discussion: This review will identify relevant literature on the topic to inform prescribers working in oncology and
malignant haematology. It will also analyse any evidence of the following outcomes: toxicity, treatment adherence and/or
QoL outcomes for patients receiving non-standard doses of oral SACT. Limitations in the evidence base may arise from
variability in both the type and quality of studies reviewed.
Systematic Review Registration: PROSPERO CRD42017076195.
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Background
Major advances in drug development have revolutio-
nised cancer treatment over the last decade [1]. Oral
systemic anticancer therapies (SACT) refer to orally ad-
ministered drugs with an antineoplastic indication and
include traditional cytotoxics (e.g. cyclophosphamide,
capecitabine, busulfan), small molecule targeted agents
(e.g. imatinib, pazopanib, sunitinib), immunomodulatory
drugs (e.g. thalidomide, lenalidomide, pomalidomide),
and hormone modulators (e.g. tamoxifen, enzalutamide,
abiraterone) [2]. Unlike injectable cytotoxic chemother-
apy, where therapeutic doses are administered at specific
days on a cyclical basis, oral SACT (particularly targeted
therapies) are given as continuous, often daily treat-
ments, with a possible scheduled break depending on
the licensed dose of the drug in question [2].
Chemotherapy dose rounding and banding is a well-
established current practice in the UK, which helps to
maintain consistent prescribing of oral SACT through-
out a patient’s treatment journey. However, daily oral
administration requires a high level of adherence to
maximise clinical benefit, which patients can find
challenging [3]. Experiences from both clinical studies
and current practice suggest that non-adherence to con-
ventional dosing of these drugs can be directly attributed
to incidents and severity of side effects [4]. Non-
adherence due to side effects can negatively affect
efficacy outcomes from treatment. In parallel, intolerable
side effects can also adversely affect patients’ QoL for
the duration of their treatment and beyond (if side ef-
fects are irreversible). Toxicities and related poor QoL
outcomes, measured by instruments such as the
European Organisation for Research and Treatment of
Cancer (EORTC) QLQ-C30 questionnaire [5], can ultim-
ately lead to dose reductions, treatment interruption or
discontinuation [6].
Drug efficacy is measured by specific disease-response
assessment criteria, such as response evaluation criteria
for solid tumours (RECIST) [7], and International
Myeloma Working Group (IMWG) criteria for multiple
myeloma [8]. To ensure safe and effective treatment, it
is necessary for prescribers (medical and non-medical)
to exercise informed decisions when practice does not
follow standard dosing. Non-conventional dosing of oral
SACT, where unlicensed doses/schedules are prescribed,
is increasingly being used to reduce adverse outcomes
described above.
There is very limited guidance on the use of non-
conventional dosing of oral SACT. For instance, there is
no guidance in the UK to recommend or govern their
non-conventional prescribing for the treatment of mul-
tiple myeloma. Therefore, this systematic review aims to
identify evidence about non-standard dosing of these
agents in oncology and malignant haematology to
inform prescribing practices. A secondary aim of this re-
view is to analyse any evidence of the following out-
comes: toxicity, treatment adherence and/or QoL
outcomes for patients receiving non-standard doses of
oral SACT to inform research questions evaluating the
feasibility of non-standard prescribing strategies for
these therapies.
Methods
Study design
The proposed systematic review will be undertaken
between March 2017 and March 2018, following an a
priori protocol, as described herein. The protocol for the
review was designed in accordance with the Preferred
Reporting Items for Systematic Review and Meta-Analy-
sis Protocols (PRISMA-P) guidelines [9], which has been
registered with the PROSPERO database
(CRD42017076195). The review will meet criteria for a
systematic review described by Grant and colleagues
[10]. It will systematically search for evidence in an
exhaustive and comprehensive manner without time
limitation or scoping constraints, and will apply prede-
fined inclusion and exclusion criteria. Quality appraisal
of studies will be integral to the review’s inclusion and
exclusion process. The review will also conduct sub-
group analyses if findings allow. Any methodological
changes from the protocol to the final review will be
documented in the subsequent manuscript and submit-
ted for publication.
Eligibility criteria
Studies will be included if they meet the following
criteria:
 Studies of malignant disease
 Studies of patients aged ≥18 years
 Studies of oral SACT with non-conventional dosing
 Studies examining the prescribing practices using
unlicensed (non-standard) doses or schedules of oral
SACT
 Meta-analysis
 Late phase clinical trials
 Cohort studies
 Cross-sectional studies
 Retrospective studies
 Observational studies
 Case-control studies
 Case-reports
 MHRA: reports, legislative documents
The following publications will be excluded:
 Studies of parenteral SACT (e.g. IM, IV, SC, IT)
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 Studies of oral SACT where non-conventional
dosing has been used, but cannot be extracted
independently of other reported data
 Studies comparing different licensed doses of oral
SACT for the same antineoplastic indication
 New standard dose-finding studies
 Animal studies
 Early phase clinical trials
 Pharmacokinetic studies
 Narrative reviews
 Opinion papers
 Education papers
 Commentaries
 Editorials
 Conference abstracts
To reduce the risk of bias generated from reviewing
interpretative secondary analysis, systematic reviews
other than meta-analyses will also be excluded. System-
atic reviews will be used to source relevant primary
research from reference lists as part of the search expan-
sion process.
Search strategy
The PROSPERO database was searched to confirm that
no systematic reviews were/are being conducted on this
subject. The following electronic resources will be
searched: Ovid MEDLINE, Ovid EMBASE, Cochrane
Registry of Controlled Trials, and Cumulative Index to
Nursing and Allied Health Literature (CINHAL). The
search expansion might also include searching the
following grey literature sources: Medicines and Health-
care Products Regulatory Agency (MHRA) website, and
Clinicaltrials.gov website.
A preliminary systematic search strategy will be tested
in order to achieve sufficient specificity while maintain-
ing high sensitivity. Boolean operators AND, and OR
will be used, as well as truncation (*). Searches will in-
clude title and abstract where possible, and will be re-
stricted to English language only. There will be no date
restriction.
Search strategy contains 3 components (drug names,
relevant MESH terms for antineoplastic agents, and all
terms describing non-conventional dosing).
Component one:
All 77 oral SACT listed in the British National Formu-
lary (BNF) will be searched as MESH terms [2]. If a drug
does not have a MESH term on any or all of the data-
bases, it will be searched for as a keyword. Search terms
for cytotoxic agents are: bexarotene, busulfan, capecita-
bine, chlorambucil, cyclophosphamide, estramustine, eto-
poside, hydroxycarbamide, melphalan, mercaptopurine,
lomustine, mitotane, procarbazine, tegafur, temozolomide,
tioguanine, topotecan, treosulfan, tretinoin, trifluridine,
vinorelbine, idarubicin, and methotrexate. Search terms
for small molecule targeted therapies are: afatinib, axitinib,
bosutinib, cabozantinib, cobimetinib, crizotinib, ceritinib,
dabrafenib, dasatinib, erlotinib, everolimus, gefitinib, ibru-
tinib, idelalisib, imatinib, lapatinib, nilotinib, nintedanib,
olaparib, osimertinib, panobinostat, pazopanib, ponatinib,
regorafenib, ruxolitinib, sorafenib, sunitinib, temsirolimus,
trametinib, vandetanib, vemurafenib, vismodegib, lenvati-
nib, palbociclib, venetoclax, and ixazomib. Search terms
for immunomodulatory drugs are: thalidomide, lenalido-
mide, and pomalidomide. Search terms for hormone mod-
ulators are: anastrozole, exemestane, letrozole, tamoxifen,
toremifene, abiraterone, bicalutamide, cyproterone, enza-
lutamide, flutamide, medroxyprogesterone, megestrol,
norethisterone, diethylstilbestrol, and ethinylestradiol.
Component two:
MEDLINE MESH: antineoplastic agents (administra-
tion and dosage), antineoplastic agents (therapeutic use),
and drug administration schedule. EMBASE MESH:
antineoplastic agent (drug administration), antineoplastic
agent (drug therapy), antineoplastic agent (oral drug
administration), antineoplastic agent (drug dose).
CINAHL MESH: antineoplastic agents (administration
and dosage), antineoplastic agents (therapeutic use), and
drug administration schedule. Cochrane Registry of
Controlled Trials keywords: drug administration, and
antineoplastic agent.
Component three:
The following terms will be used to search titles:
reduc* or attenuat* or discontinu* or modif* or dosing
or schedul* or strateg* or dosage* or intercalat* or alter-
nat* or personali* or break or holiday* or cessation or
interrup* or intermit* or escala* or prescrib* or optimis*
or optimiz* or tailor* or individuali* or “non conven-
tional*” or nonconventional* or “non standard*” or non-
standard* or “treatment free”.
Full database search strategies are shown in the follow-
ing Tables: Table 1 (MEDLINE search strategy), Table 2
(EMBASE search strategy), Table 3 (CINAHL search
strategy), and Table 4 (Cochrane Registry of Controlled
Trials search strategy).
Data management
Three researchers will independently review search re-
sults and all duplicates will be removed. All retrieved ti-
tles will be screened against inclusion and exclusion
criteria by the primary author; a quarter will be inde-
pendently assessed by another member of the research
Djebbari et al. Systematic Reviews  (2017) 6:244 Page 3 of 8
Table 1 MEDLINE search strategy
Search steps
1. Imatinib Mesylate/
2. bexarotene.mp.
3. Busulfan/
4. Capecitabine/
5. Chlorambucil/
6. Cyclophosphamide/
7. Estramustine/
8. Etoposide/
9. Hydroxyurea/ or hydroxycarbamide.mp.
10. Melphalan/
11. mercaptopurine.mp. or 6-Mercaptopurine/
12. Lomustine/
13. Mitotane/
14. Procarbazine/
15. Tegafur/
16. temozolomide.mp.
17. Thioguanine/
18. Topotecan/
19. treosulfan.mp.
20. Tretinoin/
21. Trifluridine/
22. vinorelbine.mp.
23. afatinib.mp.
24. axitinib.mp.
25. bosutinib.mp.
26. cabozantinib.mp.
27. cobimetinib.mp.
28. crizotinib.mp.
29. ceritinib.mp.
30. dabrafenib.mp.
31. Dasatinib/
32. Erlotinib Hydrochloride/
33. Everolimus/
34. gefitinib.mp.
35. ibrutinib.mp.
36. idelalisib.mp.
37. lapatinib.mp.
38. nilotinib.mp.
39. nintedanib.mp.
40. olaparib.mp.
41. osimertinib.mp.
42. panobinostat.mp.
43. pazopanib.mp.
44. ponatinib.mp.
45. regorafenib.mp.
46. ruxolitinib.mp.
47. sorafenib.mp.
48. sunitinib.mp.
Table 1 MEDLINE search strategy (Continued)
Search steps
49. temsirolimus.mp.
50. trametinib.mp.
51. vandetanib.mp.
52. vemurafenib.mp.
53. vismodegib.mp.
54. Thalidomide/
55. lenalidomide.mp.
56. pomalidomide.mp.
57. anastrozole.mp.
58. exemestane.mp.
59. letrozole.mp.
60. Tamoxifen/
61. Toremifene/
62. Abiraterone Acetate/
63. bicalutamide.mp.
64. Cyproterone/ or Cyproterone Acetate/
65. enzalutamide.mp.
66. Flutamide/
67. Medroxyprogesterone/ or Medroxyprogesterone Acetate/
68. Megestrol/ or Megestrol Acetate/
69. norethisterone.mp. or Norethindrone/
70. Diethylstilbestrol/
71. Ethinyl Estradiol/ or ethinylestradiol.mp.
72. Idarubicin/
73. Methotrexate/
74. Trifluridine/
75. lenvatinib.mp.
76. venetoclax.mp.
77. ixazomib.mp.
78. Palbociclib.mp.
79. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or
16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or
30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or
44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or
58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or
72 or 73 or 74 or 75 or 76 or 77 or 78
80. Antineoplastic Agents/ad [Administration & Dosage]
81. Antineoplastic Agents/tu [Therapeutic Use]
82. Drug Administration Schedule/
83. 80 or 81 or 82
84. (reduc* or attenuat* or discontinu* or modif* or dosing or schedul* or strateg*
or dosage* or intercalat* or alternat* or personali* or break or holiday* or
cessation or interrup* or intermit* or escala* or prescrib* or optimis* or
optimiz* or tailor* or individuali* or "non conventional*" or nonconventional*
or "non standard*" or nonstandard* or "treatment free").ab,ti.
85. (reduc* or attenuat* or discontinu* or modif* or dosing or schedul* or strateg*
or dosage* or intercalat* or alternat* or personali* or break or holiday* or
cessation or interrup* or intermit* or escala* or prescrib* or optimis* or
optimiz* or tailor* or individuali* or "non conventional*" or nonconventional*
or "non standard*" or nonstandard* or "treatment free").ti.
86. 79 and 83 and 84
87. 79 and 83 and 85
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Table 2 EMBASE search strategy
Search steps
1. Imatinib Mesylate/
2. bexarotene.mp.
3. Busulfan/
4. Capecitabine/
5. Chlorambucil/
6. Cyclophosphamide/
7. Estramustine/
8. Etoposide/
9. Hydroxyurea/ or hydroxycarbamide.mp.
10. Melphalan/
11. mercaptopurine.mp. or 6-Mercaptopurine/
12. Lomustine/
13. Mitotane/
14. Procarbazine/
15. Tegafur/
16. temozolomide.mp.
17. Thioguanine/
18. Topotecan/
19. treosulfan.mp.
20. Tretinoin/
21. Trifluridine/
22. vinorelbine.mp.
23. afatinib.mp.
24. axitinib.mp.
25. bosutinib.mp.
26. cabozantinib.mp.
27. cobimetinib.mp.
28. crizotinib.mp.
29. ceritinib.mp.
30. dabrafenib.mp.
31. Dasatinib/
32. Erlotinib Hydrochloride/
33. Everolimus/
34. gefitinib.mp.
35. ibrutinib.mp.
36. idelalisib.mp.
37. lapatinib.mp.
38. nilotinib.mp.
39. nintedanib.mp.
40. olaparib.mp.
41. osimertinib.mp.
42. panobinostat.mp.
43. pazopanib.mp.
44. ponatinib.mp.
45. regorafenib.mp.
46. ruxolitinib.mp.
47. sorafenib.mp.
48. sunitinib.mp.
Table 2 EMBASE search strategy (Continued)
Search steps
49. temsirolimus.mp.
50. trametinib.mp.
51. vandetanib.mp.
52. vemurafenib.mp.
53. vismodegib.mp.
54. Thalidomide/
55. lenalidomide.mp.
56. pomalidomide.mp.
57. anastrozole.mp.
58. exemestane.mp.
59. letrozole.mp.
60. Tamoxifen/
61. Toremifene/
62. Abiraterone Acetate/
63. bicalutamide.mp.
64. Cyproterone/ or Cyproterone Acetate/
65. enzalutamide.mp.
66. Flutamide/
67. Medroxyprogesterone/or Medroxyprogesterone Acetate/
68. Megestrol/or Megestrol Acetate/
69. norethisterone.mp. or Norethindrone/
70. Diethylstilbestrol/
71. Ethinyl Estradiol/or ethinylestradiol.mp.
72. Idarubicin/
73. Methotrexate/
74. Trifluridine/
75. lenvatinib.mp.
76. venetoclax.mp.
77. ixazomib.mp.
78. Palbociclib.mp.
79. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16
or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or
30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43
or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or
57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70
or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78
80. antineoplastic agent/ad [Drug Administration]
81. antineoplastic agent/dt [Drug Therapy]
82. antineoplastic agent/po [Oral Drug Administration]
83. antineoplastic agent/do [Drug Dose]
84. 80 or 81 or 82 or 83
85. (reduc* or attenuat* or discontinu* or modif* or dosing or schedul* or strateg* or
dosage* or intercalat* or alternat* or personali* or break or holiday* or cessation
or interrup* or intermit* or escala* or prescrib* or optimis* or optimiz* or tailor*
or individuali* or "non conventional*" or nonconventional* or "non standard*" or
nonstandard* or "treatment free").ab,ti.
86. (reduc* or attenuat* or discontinu* or modif* or dosing or schedul* or strateg* or
dosage* or intercalat* or alternat* or personali* or break or holiday* or cessation
or interrup* or intermit* or escala* or prescrib* or optimis* or optimiz* or tailor*
or individuali* or "non conventional*" or nonconventional* or "non standard*" or
nonstandard* or "treatment free").ti.
87. 79 and 84 and 85
88. 79 and 84 and 86
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team. Sources that do not meet all eligibility criteria will
be excluded. Full text publications of all remaining
sources will be obtained and screened against eligibility
criteria by the primary author. Another member of the
research team will independently screen all full text pub-
lications against eligibility criteria. Exclusion decisions of
full text publications will be agreed between the research
team after independent review. The number of excluded
sources and reasons for exclusion will be reported.
Publications reporting studies that meet all inclusion
criteria will all be included in the review.
Search expansion
An expanded search will be conducted to ensure com-
prehensive review evidence that meets inclusion criteria.
Prospective citation chaining will be conducted in the
database Web of Science to identify potentially relevant
papers that have cited included studies. Retrospective
snowballing of reference lists of included studies will
also be conducted. Sources identified during the search
expansion stage of the literature search will undergo the
screening process described above. Search and exclusion
process will be reported in accordance with PRISMA
guidelines [9].
Critical appraisal
Critical appraisal will be independently conducted by at
least two members of the research team to identify
potential bias, strengths and limitations of included
studies. Standardised critical appraisal tools will be used
to appraise the quality of studies; the tools used will
depend on the type of study design being reviewed, but
will include use of Critical Appraisal Skills Programme
(CASP) tools. The following aspects of the study will be
critiqued: soundness of study (method, quality of data
analysis and interpretation), appropriateness of study
design to answer the question (study type, sample char-
acteristics, allocations of oral SACT prescribed at non-
conventional doses, relevancy to current prescribing
practice), and quality of reported outcomes over differ-
ent time periods. The researchers will assign a quality
rating of high, medium and low to studies reviewed and
any discrepancy in quality appraisal rating will be
discussed with and resolved within the research team.
Data extraction
Members of the research team will independently
extract data using pre-defined categories into data ex-
traction tables, in order to summarise key findings for
reporting. Data extraction table is available in Table
5.Since the range of published data on the topic is not
fully known to the research team until evidence has been
systematically identified, the process of data extraction
will require an inductive approach, whereby key findings
Table 3 CINAHL search strategy
2-83: First Component (drug names):
name of each of the drug (same as Medline and Embase) as MESH
terms, if not as keyword (title/abstract). Total number of drugs is 77 but
4 drugs had two different spellings: mercaptopurine (6-mercaptopurine),
ethinylestradiol (ethinyl estradiol), norethisterone (norethindrone),
medroxyprogesterone (medroxyprogesterone acetate)
84. 2 OR 3 OR 4…..OR 21
85. 22 OR 23 OR 24 OR…OR 42
86. 43 OR 44 OR… OR 63
87. 64 OR 65….OR 83
88. MESH: "ANTINEOPLASTIC AGENTS"/ad (i.e. administration and
dosage)
89. MESH: "ANTINEOPLASTIC AGENTS"/tu (i.e. therapeutic use)
90. MESH: "DRUG ADMINISTRATION SCHEDULE"/
91. 88 OR 89 OR 90
92. Second component:
(reduc* OR attenuat* OR discontinu* OR modif* OR dosing OR schedul*
OR strateg* OR dosage* OR intercalat* OR alternat* OR personali* OR
break OR holiday* OR cessation OR interrup* OR intermit* OR escala*
OR prescrib* OR optimis* OR optimiz* OR tailor* OR individuali* OR
"non conventional*" OR nonconventional* OR "non standard*" OR
nonstandard* OR "treatment free").ti
93. 84 AND 91 AND 92 (one quarter of results, then exported)
94. 85 AND 91 AND 92 (one quarter of results, then exported)
95. 86 AND 91 AND 92 (one quarter of results, then exported)
96. 87 AND 91 AND 92 (one quarter of results, then exported)
Table 4 Cochrane Registry of Controlled Trials search strategy
1. First Component (drug names):
bexarotene or busulfan or capecitabine or chlorambucil or cyclophosphamide
or estramustine or etoposide or hydroxycarbamide or melphalan or
mercaptopurine or lomustine or mitotane or procarbazine or tegafur or
temozolomide or tioguanine or topotecan or treosulfan or tretinoin or
trifluridine or vinorelbine or afatinib or axitinib or bosutinib or cabozantinib
or cobimetinib or crizotinib or ceritinib or dabrafenib or dasatinib or
erlotinib or everolimus or gefitinib or ibrutinib or idelalisib or imatinib or
lapatinib or nilotinib or nintedanib or olaparib or osimertinib or
panobinostat or pazopanib or ponatinib or regorafenib or ruxolitinib or
sorafenib or sunitinib or temsirolimus or trametinib or vandetanib or
vemurafenib or vismodegib or thalidomide or lenalidomide or
pomalidomide or anastrozole or exemestane or letrozole or tamoxifen or
toremifene or abiraterone or bicalutamide or cyproterone or enzalutamide
or flutamide or medroxyprogesterone or megestrol or norethisterone or
diethylstilbestrol or ethinylestradiol or idarubicin or methotrexate or
trifluridine or lenvatinib or palbociclib or venetoclax or Ixazomib in Title,
Abstract, Keywords
2. Second component:
reduc* or attenuat* or discontinu* or modif* or dosing or schedul* or
strateg* or dosage* or intercalat* or alternat* or personali* or break or
holiday* or cessation or interrup* or intermit* or escala* or prescrib* or
optimis* or optimiz* or tailor* or individuali* or "non conventional*" or
nonconventional* or "non standard*" or nonstandard* or "treatment
free" in Record Title
3. "DRUG ADMINISTRATION" or "ANTINEOPLASTIC AGENT*" in Title,
Abstract, Keywords (word variations have been searched)
4. 1 AND 2 AND 3
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will be extracted from a range of study designs reporting
a range of study outcomes. Data extraction tables will be
compared and integrated to ensure all key findings are
included and accurately reported in the review. Any dis-
agreements during this process will be resolved through
discussion within the research team.
Data analysis and synthesis
Key findings (sorted and summarised during the data ex-
traction process) will be integrated and a narrative
summary/synthesis of findings will be presented and
discussed. If sufficient stratified data is available about
the population (e.g. age group, tumour type, disease
stage), or intervention (drug, dosing schedule) or out-
come (toxicity, adherence, QoL), a sub-group analysis
will be conducted to inform prescribing practice. Results
will be discussed in reference to the strengths and
weaknesses of the evidence base, and with a focus on ad-
dressing the primary aim to identify evidence about
non-conventional dosing of oral SACT in oncology and
malignant haematology.
Discussion
In clinical practice, non-conventional dosing of oral anti-
cancer drugs is becoming more common in response to
treatment toxicity and impaired adherence [4]. This ap-
proach enables prescribers to tailor prescribing decisions
for individual patients based on their needs [11]. The
main aim of this review is to identify and collate
evidence about the use of non-standard dosing of oral
SACT in oncology and malignant haematology. In
summarising evidence, the strengths and limitations of
the evidence base will be identified and discussed. A
summary of key findings will be used to inform pre-
scribers working in oncology and haematology. It will
also identify any evidence of changes in toxicity and/or
quality of life outcomes for patients receiving non-
standard doses of oral SACT. Findings of this review will
also inform a future feasibility or interventional study
evaluating non-conventional dosing of oral SACT. Limi-
tations in the evidence base may arise from variability in
both the type and quality of studies, which may restrict
the generalisability of conclusions about the use of non-
conventional dosing for oral SACT in oncology and ma-
lignant haematology.
In addition to disseminating results of this review in
an international health care journal, findings will be
presented to oncologists, nurses, pharmacists and
patient representatives within a local Cancer Alliance
and at national and international conferences.
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